Penumbra Inc
Penumbra, Inc. (NASDAQ: PEN) is the world's leading thrombectomy company focused on developing innovative technologies for challenging vascular medical conditions. The company designs, develops, manufactures, and markets novel medical devices used by specialist physicians to treat ischemic stroke, venous… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Penumbra Inc does
In the company’s own words
Penumbra, Inc. (NASDAQ: PEN) is the world's leading thrombectomy company focused on developing innovative technologies for challenging vascular medical conditions. The company designs, develops, manufactures, and markets novel medical devices used by specialist physicians to treat ischemic stroke, venous thromboembolism including pulmonary embolism, acute limb ischemia, deep vein thrombosis, coronary disease, and various other vascular disorders. Founded in 2004, Penumbra operates as a single reportable segment with two primary product categories: thrombectomy and embolization and access.
The thrombectomy product line, which generated approximately 67% of revenue, includes the Indigo System for peripheral thrombectomy applications and the Penumbra System for neuro thrombectomy procedures. These systems leverage computer-assisted vacuum thrombectomy technology to remove blood clots with speed and safety. The embolization and access product line, representing approximately 33% of revenue, comprises peripheral and neuro embolization products such as the Ruby Embolization Platform and Penumbra Coil families, along with access products including the Neuron and BENCHMARK catheter families. The company also offers neurosurgical tools including the Artemis Neuro Evacuation Device.
Penumbra sells its products directly in the United States, most of Europe, Canada, Australia, and Singapore, with approximately 90% of revenue from direct sales and the remainder from international distributors and licensing arrangements. The company maintains manufacturing facilities in Alameda and Roseville, California, where substantially all products are produced in-house. The company holds 125 issued patents globally and 235 foreign trademark registrations supporting its proprietary technology portfolio.
On January 14, 2026, Penumbra entered into a merger agreement with Boston Scientific Corporation valuing the company at approximately $14.5 billion, with the transaction expected to close by the end of 2026. More information is available at www.penumbrainc.com.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- ALAMEDA, CA
- Fiscal year end
- December
- CIK
- 1321732
- SIC
- 3841
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Penumbra Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Penumbra Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Penumbra Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Penumbra Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Penumbra Inc's last four quarterly filings that the numbers alone won't show?”